Theorem strengthens cardiovascular service with strategic alliance

By Dan Stanton

- Last updated on GMT

Related tags: Contract research organization, Clinical trial

Theorem strengthens cardiovascular service with strategic alliance
Theorem strengthens cardiovascular service with strategic alliance
Theorem has partnered with BioTelemetry in order to offer its clients cardiovascular testing services.

BioTelemetry was formed last April and amongst its divisions it includes Cardiocore, a clinical trial firm that offers services including electrocardiography (ECG), Holter monitoring, blood pressure monitoring and (BPM), and echocardiography (ECHO).

By partnering with BioTelemetry, contract research organization (CRO) Theorem will be able to offer its clients such services across all clinical phases and is part of the firm’s strategy to offer “clients the very best in every service area​,” according to CEO John Potthoff.

He continued: “BioTelemetry reinforces that strategy with a team of industry-leading scientists, a set of advanced technologies and a broad base of cardiac testing modalities. Theorem clients will benefit from BioTelemetry’s expert consulting services and deep experience across all major therapeutic areas.”

Furthermore, the deal helps Theorem meet the ever-changing industry standards, Potthoff continued, with areas such as “safety monitoring boards, translational medicine and risk-based monitoring” ​adding “pressures on the clinical trial process to be faster, safer and more efficient.”

Mid-Sized Growth

Theorem is a mid-sized CRO and although some experts have predicted​ such companies will be either squeezed out of the market or forced to consolidate (for example last year’s merger of PRA and RPS​), this alliance supports Theorem’s own growth strategy.

Speaking to Outsourcing-Pharma.com in November at Partnerships in Clinical Trials (PCT) Vienna, Potthoff said​ there are areas of business the firm wanted to reinforce through both strategic alliances and acquisitions.

In September, Theorem partnered with Charles River Laboratories​ in order to help its clients smoothly transition between preclinical and clinical testing.

Furthermore, a new credit line with GE Capital was obtained in July and the firm’s SVP and CFO Jason Monteleone told this publication​ it was looking to “strengthen its current capabilities”​ adding “anything from a decent-sized acquisition to a mid-sized CRO.”

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars